| Pulmonary Arterial Hypertension |
1 |
1 |
| Prostacyclin |
0 |
0.62 |
| Endothelin Receptor Antagonists |
0 |
0.33 |
| Europe |
0 |
0.31 |
| Intravenous |
0 |
0.31 |
| Receptors |
0 |
0.31 |
| Connective Tissue Disease |
0 |
0.22 |
| Heart Failure (HF) |
0 |
0.2 |
| Hypertension |
0 |
0.19 |
| Adverse Effects |
0 |
0.15 |
| Blood |
0 |
0.15 |
| California |
0 |
0.15 |
| Clinical Guidelines |
0 |
0.15 |
| Comparative Effectiveness |
0 |
0.15 |
| Food and Drug Administration (FDA) |
0 |
0.15 |
| Health Care Economics |
0 |
0.15 |
| Hemoglobin |
0 |
0.15 |
| Pulmonary Hypertension |
0 |
0.15 |
| Quality of Life |
0 |
0.15 |
| Telangiectasia |
0 |
0.15 |
| Tissue |
0 |
0.15 |
| Biologic Therapy |
0 |
0.1 |
| Neuroendocrine Tumor |
0 |
0.1 |
| Patient Safety |
0 |
0.1 |
| Social Determinants of Health |
0 |
0.1 |